In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anesiva, Inc.

https://www.anesiva.com/

Latest From Anesiva, Inc.

Medicare Negotiation Round Two Will Be Dominated By Oral Cancer Drugs, Researchers Predict

A number of diabetes drugs are also expected to be targeted in the next cycle of the price negotiation program, led by Novo Nordisk’s Ozempic.

Medicare Reimbursement

FTC’s PBM Investigation Could Yield Litigation Over Insulin Contracting

The US Federal Trade Commission’s focus on potential anti-competitive behavior by pharmacy benefit managers picks up steam as Chair Lina Khan approaches the end of her term.

Reimbursement Pricing Debate

FTC’s PBM Investigation Could Yield Litigation Over Insulin Contracting

The US Federal Trade Commission’s focus on potential anti-competitive behavior by pharmacy benefit managers picks up steam as Chair Lina Khan approaches the end of her term.

Reimbursement Pricing Debate

Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

Deals StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AlgoRx Pharmaceuticals
    • Corgentech
UsernamePublicRestriction

Register